FHTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FHTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Foghorn Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $0.00 Mil. Foghorn Therapeutics's average total debt for the quarter that ended in Dec. 2023 was $46.08 Mil. Therefore, Foghorn Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 0.00%.
The historical data trend for Foghorn Therapeutics's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Foghorn Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | 4.57 | 1.99 | 2.72 | - | - |
Foghorn Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Foghorn Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's Effective Interest Rate on Debt % falls into.
Foghorn Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (A: Dec. 2022 ) | + | Total Debt (A: Dec. 2023 )) | / count ) |
= | -1 * 0 | / | ( (51.507 | + | 45.073) | / 2 ) |
= | -1 * 0 | / | 48.29 | |||
= | 0.00 % |
where
Total Debt (A: Dec. 2022 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 45.537 | + | 5.97 |
= | 51.507 |
Total Debt (A: Dec. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 36.555 | + | 8.518 |
= | 45.073 |
Foghorn Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (Q: Sep. 2023 ) | + | Total Debt (Q: Dec. 2023 )) | / count ) |
= | -1 * 0 | / | ( (47.082 | + | 45.073) | / 2 ) |
= | -1 * 0 | / | 46.0775 | |||
= | 0.00 % |
where
Total Debt (Q: Sep. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 38.71 | + | 8.372 |
= | 47.082 |
Total Debt (Q: Dec. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 36.555 | + | 8.518 |
= | 45.073 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.
Foghorn Therapeutics (NAS:FHTX) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Thank you for viewing the detailed overview of Foghorn Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.
Alfonso Quintas Cardama | officer: Chief Medical Officer | C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142 |
Samuel Agresta | officer: Chief Medical Officer | 784 MEMORIAL DR., CAMBRIDGE MA 02139 |
Lynch Thomas J. Jr. | director | 800 HOWARD AVENUE, YALE PHYSICIANS BUILDING, 2ND FLOOR, NEW HAVEN CT 06519 |
B Lynne Parshall | director | 2855 GAZELLE COURT, CARLSBAD CA 92010 |
Carlos Costa | officer: Chief People Officer | C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139 |
Fanny Cavalie | officer: Chief Strategy/Bus Ops Officer | C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139 |
Ian F Smith | director | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Michael Lacascia | officer: Chief Legal Officer | 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139 |
Carl Decicco | officer: Chief Scientific Officer | 100 BINNEY STREET, SUITE 610, CAMBRIDGE MA 02142 |
Flagship Ventures Opportunities Fund I General Partner Llc | 10 percent owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
Abu Dhabi Investment Authority | 10 percent owner | 211 CORNICHE STREET, PO BOX 3600, ABU DHABI C0 0000 |
Michael Mendelsohn | director | C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
Adam Koppel | director | C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116 |
Steven F. Bellon | officer: See Remarks | 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139 |
Jose Baselga | director | 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
From GuruFocus
By sperokesalga sperokesalga • 05-08-2023
By Marketwired • 10-24-2023
By Value_Insider Value_Insider • 11-22-2022
By Marketwired • 11-02-2023
By Stock market mentor Stock market mentor • 01-09-2023
By Value_Insider Value_Insider • 11-08-2022
By PRNewswire PRNewswire • 04-27-2023
By sperokesalga sperokesalga • 06-07-2023
By Value_Insider Value_Insider • 11-09-2022
By Value_Insider Value_Insider • 10-20-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.